

Dear Duchenne Community,

Date: April 28, 2026

At Precision BioSciences, we are committed to advancing research for people living with Duchenne muscular dystrophy. We understand the urgency families feel and the importance of developing new approaches that may lead to meaningful improvements in people's lives.

Earlier this year, we were pleased to announce that the U.S. Food and Drug Administration (FDA) cleared our Investigational New Drug (IND) application for our PBGENE-DMD program, an important milestone that enabled us to begin preparing clinical trial sites and advance into clinical studies.

Today, we are pleased to share another important milestone: our first clinical trial site is now open at Arkansas Children's Hospital (Little Rock, AR) with Dr. Aravindhan Veerapandiyan as the study's principal investigator. This marks the beginning of the next phase of our clinical study, where we will work with doctors, researchers, and families to better understand the safety profile and potential benefits of PBGENE-DMD.

PBGENE-DMD is our investigational gene editing program designed to address the underlying cause of Duchenne. This approach aims to make a precise change directly within the dysfunctional dystrophin gene with the goal of helping the body produce a more complete and functional version of the dystrophin protein, which plays an important role in keeping muscles healthy.

This work is being studied in the FUNCTION-DMD clinical trial (NCT07429240), which is designed to evaluate the safety of the one-time study treatment and its potential effects on muscle health and function over time. The study focuses on boys aged 2-7 with specific genetic changes in exons 45-55 of the dystrophin gene, which are common in Duchenne.

We know that families are looking for clear and reliable information. As the study progresses, we will continue to share updates about additional sites, enrollment, and what we are learning along the way. We are committed to communicating in a way that is transparent and easy to understand.

Our team remains focused on advancing this research responsibly and thoughtfully, with the hope of making a meaningful difference for people living with Duchenne. We look forward to keeping you informed as we move ahead.

For questions about the FUNCTION-DMD trial, please contact our Patient Advocacy team at [patientadvocacy@precisionbiosciences.com](mailto:patientadvocacy@precisionbiosciences.com)

Sincerely,

**Cindy Atwell**  
Chief Development Officer  
Precision Biosciences